Yellow fever-associated viscerotropic disease in Barcelona, Spain.

  title={Yellow fever-associated viscerotropic disease in Barcelona, Spain.},
  author={Jos{\'e} Esteban Mu{\~n}oz and Anna Vilella and Cristina Domingo and Josep Mar{\'i}a Nicol{\'a}s and Fernando de Ory and Manuel Corach{\'a}n and Antonio Tenorio and J. Gascon},
  journal={Journal of travel medicine},
  volume={15 3},
Yellow fever vaccine is a live, attenuated viral preparation from the 17D virus strain. Since 1996, 34 cases of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) have been described. We report a new case of YEL-AVD. Given the potential risks associated with the vaccine, physicians should consider vaccination only for patients truly at risk for exposure to yellow fever, especially for primovaccination. 

From This Paper

Figures, tables, and topics from this paper.


Publications referenced by this paper.
Showing 1-10 of 16 references

Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil

Vasconcelos PFC, JE Bryant, PA TravassosdaRosa
Vaccine • 2006

Yellow fever vaccine-associated viscerotropic disease and death in Spain.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology • 2006

Eidex for the Yellow Fever Vaccine Safety Working Group . History of thymoma and yellow fever vaccination

R Barwick
Lancet • 2004

Similar Papers

Loading similar papers…